Prostate Cancer

Dr. Mary-Ellen Taplin, from Dana-Farber Cancer Institute, on Neoadjuvant Abiraterone Acetate and Leuprolide Acetate

Patients with metastatic, hormone-sensitive prostate cancer and minimal disease spread experience a two-year boost in median survival when treated with continuous, rather than intermittent, hormonal therapy.

Dr. Raoul Concepcion, from Urology Associates, PC, Nashville, TN, Discusses New Prostate Cancer Therapies.

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on the Unique Attributes of Neoadjuvant Zytiga.

To date, no studies of novel therapies combined with docetaxel and prednisone have demonstrated improvement in their designated endpoints. However, several promising combination trials are ongoing.

Focal therapy offers some men with localized prostate cancer a solution between active surveillance and definitive treatment with surgery and/or radiation.

Dr. Paul Sieber, from the Urological Association of Lancaster, on Managing Bone Health After the Introduction of ADT.

Oliver Sartor, MD, and Leonard G. Gomella, MD, discuss multiple topics involved with prostate-specific antigen (PSA) screening, including PSA velocity, guidelines, and cutoff age.

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

The USPSTF has made a final recommendation against routine screening for prostate cancer in asymptomatic males through PSA testing.

Dr. Leonard Gomella, form the Jefferson Kimmel Cancer Center, on the Impact of the New USPSTF PSA Rating.

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses Prostate-Specific Antigen (PSA) Screening

Dr. Leonard Gomella, from the Jefferson Kimmel Cancer Center, on the Provenge IMPACT Trial Survival Benefit

Leonard G. Gomella, MD, discusses the public policy and medical implications of the US Preventive Services Task Force's draft recommendation on PSA screening.

The prostate cancer drug abiraterone acetate is expected be provided for patients through England's publicly funded healthcare system after NICE reversed its initial recommendation.

Dr. Andrew Goy, from John Theurer Cancer Center, on Neoadjuvant Hormonal Therapy Plus Zytiga

Combined neoadjuvant treatment with abiraterone acetate (Zytiga) plus standard hormonal therapy before prostatectomy eradicated or nearly eradicated tumors in 34% of patients with localized high-risk prostate cancer.

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on Neoadjuvant Hormonal Therapy Combined With Abiraterone Acetate

Now, with four new agents approved in the last two years and two promising agents in the pipeline, therapy selection and potential outcomes are changing.

Men with low-risk prostate cancer who have opted for active surveillance are about half as likely to experience pathologic progression or abandon active surveillance if they take a 5-ARI.

The neoadjuvant administration of sipuleucel-T may stimulate an immune response in patients with localized prostate cancer without adversely affecting their surgeries.

Dr. Robert Dreicer, from the Cleveland Clinic, on Utilizing New Prostate Cancer Therapies

Dutasteride may postpone disease progression in men with low-risk prostate cancer who have opted for an active surveillance strategy.

Nurses play vital roles in assuring that patients with metastatic castration-resistant prostate cancer (mCRPC) are optimally treated with sipuleucel-T.

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses PSA Velocity